Jefferies Financial Group Inc. Boosts Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Jefferies Financial Group Inc. lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 167.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,216,954 shares of the company's stock after acquiring an additional 762,147 shares during the period. Jefferies Financial Group Inc. owned 2.37% of Spyre Therapeutics worth $28,331,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Barclays PLC increased its position in Spyre Therapeutics by 64.7% during the 3rd quarter. Barclays PLC now owns 105,467 shares of the company's stock valued at $3,101,000 after buying an additional 41,424 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Spyre Therapeutics during the 4th quarter valued at approximately $290,000. JPMorgan Chase & Co. increased its position in Spyre Therapeutics by 19.6% during the 4th quarter. JPMorgan Chase & Co. now owns 35,248 shares of the company's stock valued at $821,000 after buying an additional 5,775 shares in the last quarter. Victory Capital Management Inc. bought a new position in Spyre Therapeutics during the 4th quarter valued at approximately $6,241,000. Finally, First Trust Advisors LP bought a new position in Spyre Therapeutics during the 4th quarter valued at approximately $548,000. Institutional investors own 80.39% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SYRE. Leerink Partners began coverage on Spyre Therapeutics in a research report on Tuesday, April 8th. They set an "outperform" rating and a $45.00 price objective for the company. Wolfe Research assumed coverage on Spyre Therapeutics in a report on Tuesday, March 18th. They issued an "outperform" rating and a $27.00 target price for the company. Wedbush reissued an "outperform" rating and issued a $65.00 target price on shares of Spyre Therapeutics in a report on Monday, May 5th. Leerink Partnrs raised Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, April 8th. Finally, The Goldman Sachs Group raised Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Spyre Therapeutics currently has an average rating of "Buy" and an average target price of $53.40.

Spyre Therapeutics Stock Performance

Shares of SYRE traded up $0.64 during mid-day trading on Friday, reaching $15.18. The stock had a trading volume of 339,680 shares, compared to its average volume of 611,151. The firm has a market cap of $914.99 million, a price-to-earnings ratio of -2.03 and a beta of 2.78. Spyre Therapeutics, Inc. has a 12 month low of $10.91 and a 12 month high of $40.26. The business has a fifty day moving average of $14.99 and a 200 day moving average of $21.59.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.02. On average, research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).